Amanda Lea Steinberger DO, Presenter: Nothing to Disclose

Oleg Teytelboym MD, Abstract Co-Author: Nothing to Disclose

1. Understanding tumor biology and appropriate imaging utilization to guide clinical decision-making 2. Appropriate use of imaging, particularly FDG PET-CT, may obviate the standard biopsy based approaches for lymph node staging of lung cancer 3. Early stage lung cancer detected at screening may have little metastatic potential, requiring primarily local therapy 4. Routinely used biopsy based lymph node staging has a morbidity burden, and may not significantly reduce surgical upstaging  

1. Review and illustrate  AJCC 7th ed of TNM staging for lung cancer 2. Review the National Comprehensive Cancer Network guidelines for N-staging lung cancer 3. Address the role of mediastinoscopy and other interventional biopsy techniques in staging of potentially resectable lung cancer 4. Describe current treatment approaches to potentially curable lung cancer and review implications for N-staging 5. Review accuracy of CT imaging for N-staging and utility of various size based cutoffs 6. Discuss the usage of FDG PET-CT in evaluating lymph nodes a. Review SUV based cut offs b. Illustrate FDG PET-CT pitfalls 7. Review utilization of emerging techniques such as MRI for N staging of lung cancer 8. Provide practical protocols for dealing with typical staging dilemmas in work up of early lung cancer detected at screening

http://abstract.rsna.org/uploads/2014/14018585/14018585_dat9.pdf

Steinberger, A, Teytelboym, O, The N Staging of Lung Cancer: To Biopsy or Not to Biopsy.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14018585.html